StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Neulasta (pegfilgrastim by Quarter

Neulasta (pegfilgrastim — Febrile Neutropenia) — Rest of World (ROW) product sales ($M) ($M)

QuarterlyAnnual

Amgen Neulasta (pegfilgrastim: $15M in Q2 2026, down 21.1% from a year earlier. That is the lowest of the 38 quarters on record here.

Latest, Q2 2026
15
Period ended Jun 30, 2026
Change on a year earlier
-21.1%
19 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below

Where the Q2 2026 figure comes from

“|| Neulasta ® | 164 | 15 | 179 | 82 | *”

Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNeulasta (pegfilgrastim — Febrile Neutropenia) — Rest of World (ROW) product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202615-21.1%Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202616-20.0%Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 202517-34.6%Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202520-23.1%Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 202519-36.7%Form 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 202520-35.5%Form 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗
Q4 2024Dec 31, 202426-16.1%Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 202426-18.7%Form 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 202430-18.9%Form 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2024Mar 31, 202431-18.4%Form 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗
Q4 2023Dec 31, 202331-8.8%Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 202332-23.8%Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 202337-21.3%Form 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 202338-13.6%Form 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 202234-34.6%Form 10-K (filed 2023-02-09) ↗
Q3 2022Sep 30, 202242-23.6%Form 10-Q (filed 2022-11-04) ↗

Cite this data

StockData. (2026). Amgen Neulasta (pegfilgrastim ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-neulasta-row

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.